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Purpose: We evaluated the usefulness of the nuclear matrix protein 22 BladderChek 
(NMP22BC) test for the screening and follow-up of bladder cancer.
Materials and Methods: From February 2006 to September 2009, we enrolled 1,070 
patients who had hematuria or who were being followed up for bladder cancer. We com-
pared the sensitivity and specificity of the NMP22BC test with those of urine cytology.
Results: The sensitivity of the NMP22BC test (77.5%) was significantly higher than 
that of urine cytology (46.3%). The specificity of the NMP22BC test was 88.8%, com-
pared with 97.9% for urine cytology. The sensitivity of the NMP22BC test (81.8%) in 
non-muscle-invasive bladder cancer was higher than that of cytology (36.4%). However, 
the sensitivity of the NMP22BC test and of urine cytology in invasive bladder cancer 
were 57.1% and 92.9%, respectively. The sensitivity of the NMP22BC test was higher 
for low-grade bladder cancer (83.9%) than for high-grade (62.5%), and the sensitivity 
of cytology was higher for high-grade bladder cancer (66.7%) than for low-grade (37.5%). 
Follow-up bladder cancer was detected in 262 patients. The sensitivity of the NMP22BC 
test in that group (72.7%) was decreased and the specificity (91.7%) was increased. The 
sensitivity of cytology (54.5%) in the follow-up group was increased and the specificity 
(95.6%) was decreased. The presence of pyuria was significantly associated with the 
lower specificity of the NMP22BC test.
Conclusions: The greater sensitivity of the NMP22BC test may be more useful for the 
diagnosis of non-muscle-invasive bladder cancer and low-grade bladder cancer than 
for the diagnosis of invasive or high-grade bladder cancer. If the NMP22BC test is per-
formed in the absence of pyuria, it may play a compensatory role for urine cytology.
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INTRODUCTION
More than 95% of bladder cancers are transitional cell car-
cinomas that originate from transitional epithelial cells. 
Most detected cases are non-muscle-invasive bladder can-
cer that can be completely resected by transurethral blad-
der tumor resection. Nonetheless, the recurrence rate is 
high, and non-muscle-invasive bladder cancer can occa-
sionally progress to invasive bladder cancer or metastatic 
bladder cancer. Therefore, early diagnosis and compre-
hensive, regular follow-up have an important influence on 
the prognosis of bladder cancer [1].
　Cystoscopy and urine cytology are usually performed for 
the early detection of bladder cancer and in the assessment 
of recurrence. However, cystoscopy causes pain and dis-
comfort in patients, and in cases of small tumors or carcino-
ma in situ, a diagnosis may not be readily made. Urine cy-
tology has the advantage of high specificity, but it also has 
shortcomings: its sensitivity for well-differentiated or 
low-grade disease is low and may differ depending on exam-
iners [2].
　To overcome such shortcomings of the existing diag-
nostic methods for bladder cancer, diverse tumor markers 
have been investigated [3-5]. For example, the nuclear ma-
trix protein (NMP)-22 test detects nuclear matrix protein 
in urine. This protein is produced during cell division and 
is associated with transitional epithelial cancer [6]. 
Recently, the NMP22BladderChek (NMP22BC) test 
(Matritech, USA) was developed and approved by the US 
Food and Drug Administration to be used for the diagnosis Korean J Urol 2010;51:88-93
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TABLE 1. Overall results of the NMP22BladderChek test and urine cytology
NMP22BladderChek Urine cytology
p-value
Positive Negative Positive Negative
Bladder cancer (n=80)
No bladder cancer (n=990)
Sensitivity (%)
Specificity (%)
62 18
111 879
77.5
88.8
37 43
21 969
46.3
97.9
＜0.001
＜0.001
of bladder cancer and for follow-up tests. The previously 
used NMP22 test applied enzyme-linked immunosorbent 
assays (ELISAs), which were performed in laboratories, 
and involved the collection of several samples. Thus, the 
urine samples had to be stored refrigerated, the test period 
could be long, and additional equipment and personnel 
were required for reading the results. Accordingly, al-
though it was approved in 1996, the NMP22 test saw lim-
ited use in clinics. The NMP22BC test that we used in the 
present study can be performed immediately after collect-
ing a patient's urine in an outpatient clinic. Thus, it has the 
advantage that the results can be readily obtained and ad-
ditional tests can be done immediately. Here we assessed 
the efficacy of the NMP22BC test in the diagnosis of bladder 
cancer as well as for follow-up, and compared the results 
with those for urine cytology and microscopic urine 
analysis.
MATERIALS AND METHODS
1. Subjects
We studied 1,070 patients who visited our hospital for hem-
aturia or for follow-up for bladder cancer from February 
2006 to September 2009. We performed the NMP22BC 
test, urine cytology applying Tripath thin-layer technol-
ogy, and microscopic urine analysis. Of the 1,070 patients, 
650 were male and 420 were female; the patients’ mean 
ages were 59.0±15.3 years and 59.8±14.3 years, respec-
tively. Of the 1,070 patients, 262 were being followed up for 
bladder cancer; the mean age of this subgroup was 
65.2±13.0 years, and the group included 192 males and 70 
females. Of the 1,070 cases, 80 were diagnosed as having 
bladder cancer by this study. To minimize false-positives, 
patients with a past history of urinary tract infection, cys-
titis, or urolithiasis were excluded. For upper urinary tract 
evaluation, the findings were confirmed by ultrasono-
graphy or intravenous pyelography or abdomen computed 
tomography. For macroscopic hematuria evaluation, the 
findings were confirmed by cystoscopy. Microscopic urine 
analysis was done for all patients.
2. Methods
NMP22BC tests were done according to the recom-
mendations of the manufacturer. Urine was collected after 
being retained in the bladder for longer than 2 hours. Drops 
of fresh urine were applied to the NMP22BC kit within 2 
hours of collection, and the results were read after 30 
minutes. Results showing a vertical line in both the control 
window and the test window were read as positive. A verti-
cal line appearing in the control window indicated that the 
test was performed correctly. The test was effective in all 
subjects. The diagnosis of bladder cancer was confirmed by 
histological tests after resection, and the degree of cell dif-
ferentiation was determined by application of the 1998 
World Health Organization/International Society of Uro-
logical Pathology (WHO/ISUP) standard.
　To explain false-positives on the NMP22BC test in pa-
tients without bladder cancer, microscopic urine analysis 
was performed on a specimen identical to the one used for 
the NMP22BC test, and the factors that could give rise to 
a false-positive result were analyzed. Variables for the as-
sessment of the efficiency of the test were calculated as 
follows. Sensitivity was calculated as true positive/(true 
positive＋false negative)x100, and specificity was calcu-
lated as true negative/(true positive＋false positive)x100. 
For statistical calculations, we used SPSS version 12.0 
(SPSS, USA). We used the chi-square test, the Fisher’s ex-
act test, and the McNemar test, and p-values less than 0.05 
were considered to be significant.
RESULTS
The results of the NMP22BC testing were positive for 173 
cases (16.2%) out of a total of 1,070 patients; for urine cytol-
ogy, the results were positive for 58 cases (5.4%). The sensi-
tivity of the NMP22BC test was 77.5%, which was higher 
than the sensitivity of urine cytology, which was 46.3%. 
The specificity of the NMP22 test was 88.8%, which was 
lower than the 97.9% specificity of urine cytology (Table 1). 
A total of 880 patients visited our hospital for hematuria; 
the sensitivity (80.9%) of the NMP22BC test was increased 
in this group but the specificity (87.9%) of the test was de-
creased; for urine cytology, the sensitivity (40.4%) in this 
group was decreased but the specificity (98.6%) was in-
creased (p＜0.01) (Table 2).
　For the 262 patients under follow-up observation, the 
sensitivity (72.7%) of the NMP22BC test was decreased but 
the specificity (91.7%) was increased. For urine cytology, 
by contrast, the sensitivity (54.5%) was increased in the fol-
low-up group but the specificity (95.6%) was decreased (but 
this difference was not statistically significant) (p＞0.05) 
(Table 3). During the study, 80 patients (7.5%) were diag-
nosed with bladder cancer. Among the 80 cases, 66 had 
non-muscle-invasive bladder cancer and 14 had invasive Korean J Urol 2010;51:88-93
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TABLE 3. NMP22 BladderCheck test and urine cytology in patients who were seen for follow-up of bladder cancer
NMP22BladderChek Urine cytology
p-value
Positive Negative Positive Negative
Bladder cancer (n=33)
No bladder cancer (n=229)
Sensitivity (%)
Specificity (%)
24 9
19 210
72.7
91.7
18 15
10 219
54.5
95.6
0.238
0.078
TABLE 4. NMP22BladderChek test and urine cytology for detecting bladder cancer according to tumor stage
NMP22BladderChek Urine cytology p-value
Non invasive (n=66)
Invasive (n=14)
p-value
54/66 (81.8%)
8/14 (57.1%)
0.073
24/66 (36.4%)
13/14 (92.9%)
＜0.001
＜0.001
　0.063
Non invasive: non muscle invasive bladder cancer, Invasive : muscle invasive bladder cancer
TABLE 5. NMP22BladderChek test and urine cytology for detecting bladder cancer according to tumor grade
NMP22BladderChek Urine cytology p-value
Low grade (n=56)
High grade (n=24)
p-value
47/56 (83.9%)
15/24 (62.5%)
0.035
21/56 (37.5%)
16/24 (66.7%)
0.016
＜0.001
　1.000
TABLE 2. NMP22 BladderCheck test and urine cytology in patients who were seen for hematuria evaluation
NMP22BladderChek Urine cytology
p-value
Positive Negative Positive Negative
Bladder cancer (n=47)
No bladder cancer (n=761)
Sensitivity (%)
Specificity (%)
38 9
92 669
80.9
87.9
19 28
11 750
40.4
98.6
＜0.001
＜0.001
bladder cancer. Among the diagnosed patients, the sensi-
tivity of the NMP22BC test for non-muscle-invasive blad-
der cancer was 81.8%, which was higher than the 36.4% 
sensitivity for urine cytology (p＜0.01). However, for the 14 
patients with invasive cancer, the sensitivity of urine cytol-
ogy was 92.9%, which was higher than the 57.1% sensi-
tivity of the NMP22BC test, but this difference was not stat-
istically significant (p＞0.05) (Table 4).
　When bladder cancer was classified according to differ-
entiation grade, there were 56 low-grade cases and 24 
high-grade cases. When sensitivity was calculated accord-
ing to tumor grade, the NMP22BC test had a sensitivity of 
83.9% and urine cytology had a sensitivity of 37.5% for 
low-grade cancer (p＜0.01); for high-grade tumors, the sen-
sitivity of the NMP22BC test was 62.5% and that for urine 
cytology was 66.7% (the difference was not statistically sig-
nificant; p＞0.05) (Table 5).
　To evaluate the cause of the low false-positive rate for the 
NMP22BC test, microscopic urine analysis was done on an 
identical urine specimen. For the 990 patients who were 
not diagnosed as having bladder cancer, and based on the 
white blood cells (WBC) detected by microscopic urine anal-
ysis (5 WBC/high power field (HPF)), the specificity of the 
NMP22BC test was increased to 92.7% for the group with 
≤5 WBC/HPF but decreased to 66.9% for the group with 
＞5 WBC/HPF.
　Among the 990 patients, 808 had hematuria. The specif-
icity of the NMP22BC test was 59.2% in the hematuria 
group with ＞5 WBC/HPF and 89.6% in the hematuria 
group with ≤5 WBC/HPF (p＜0.01). Likewise, in patients 
undergoing follow-up for bladder cancer, the specificity of 
the NMP22BC test was 90.8% in the group with ＞5 
WBC/HPF and 47.7% in patients with ≤5 WBC/HPF 
(Table 6).
　Among the 990 patients who were not diagnosed as hav-
ing bladder cancer, the specificity of urine cytology in-
creased to 98.6% in the overall group with ≤5 WBC/HPF 
but decreased to 94.0% in the overall group with ＞5 
WBC/HPF. In the hematuria group, the specificity of urine 
cytology was 98.3% in those with ＞5 WBC/HPF and 87.5% Korean J Urol 2010;51:88-93
Usefulness of the NMP22BladderChek Test 91
TABLE 6. Specificity of the NMP22BladderChek test according to pyuria in patients without bladder cancer
No. of patients with NMP22BC negative/
No. of patients tested with urine analysis
Specificity (%) p-value
Overall (n=990)
　≤5 WBC/HPF
　＞5 WBC/HPF
Group with hematuria (n=808)
　≤5 WBC/HPF
　＞5 WBC/HPF
Follow up of bladder cancer (n=262)
　≤5 WBC/HPF
　＞5 WBC/HPF
778/839
101/151
588/656
90/152
198/218
21/44
92.7
66.9
89.6
59.2
90.8
47.7
＜0.001
＜0.001
＜0.001
NMP22BC: NMP22BladderChek, WBC: white blood cells, HPF: high power field
TABLE 7. Specificity of urine cytology according to pyuria in patients without bladder cancer
No. of patients with urine cytologynegative/
No. of patients tested with urine analysis
Specificity (%) p-value
Overall (n=990)
　≤5 WBC/HPF
　＞5 WBC/HPF
Group with hematuria (n=808)
　≤5 WBC/HPF
　＞5 WBC/HPF
Follow up of bladder cancer (n=262)
　≤5 WBC/HPF
　＞5 WBC/HPF
827/839
142/151
645/656
133/152
207/218
27/44
98.6
94.0
98.3
87.5
95.0
89.3
＜0.001
＜0.001
＜0.001
WBC: white blood cells, HPF: high power field 
in those with ≤5 WBC/HPF (p＜0.01). Likewise, in the pa-
tients undergoing follow-up for bladder cancer, the specif-
icity of urine cytology was 95.0% in those with ＞5 WBC/ 
HPF and 89.3% for cases with ≤5 WBC/HPF (Table 7).
DISCUSSION
Because of the high recurrence rates and progression of 
bladder cancer, diagnosis and follow-up observations are 
critical. Urine cytology has been performed as a general 
test for the diagnosis of bladder cancer. However, depend-
ing on disease stage and differentiation grade, urine cytol-
ogy shows low sensitivity (30-50%) [7-9]. Even among pa-
tients treated for bladder cancer and undergoing follow-up, 
satisfactory results have not been obtained by regular cys-
toscopic examination or by urine cytology (except in a few 
cases). Hence, additional tests are needed. Diverse studies 
have been conducted to develop methods that can diagnose 
bladder cancer readily by using a patient's urine. Such bio-
markers include the detection of hematuria, bladder tumor 
antigen (BTA) stat, BTA-TRAK, NMP22, BLCA-4 and 
BCLA-1, survivin, cytokeratin, HA-HAase test, micro-
satellite analysis, telomerase, uCyt, and the Urovysion 
test applying fluorescence in situ hybridization (FISH) [3]. 
When used as screening tests in high-risk patients, these 
tests have been shown to be effective for early detection and 
to reduce costs [3].
　NMP is present in low concentrations in urine and in nor-
mal cells. However, in tumor cells, it is increased 80-fold. 
Thus, in cases of bladder cancer, it is excreted in urine in 
high concentrations. The target antigen NMP22 or nuclear 
mitotic apparatus (NuMA) protein of the NMP22BC test 
is present within epithelial cells and during cell division. 
It aids in the production of the spindle and the reformation 
of the nucleus [10]. The NMP22BC test (Matritech) was de-
veloped as one such tumor marker, and numerous in-
stitutions have reported studies conducted on it [3-5,11]. 
The previously used NMP22 test method using ELISA is 
performed in laboratories after the collection of several 
specimens. Hence, urine samples must be stored refri-
gerated. Because the test cannot be conduced until all 
specimens are collected, the test period is longer, and addi-
tional equipment and personnel are required for reading 
the results. Although it was approved by the US Food and 
Drug Administration in 1996, it is not actually used in 
clinics. The NMP22BC used in our study has the advantage 
that the test can be performed immediately after the collec-
tion of urine from a patient in an outpatient clinic, and thus 
rapid results can be obtained, and the value of additional 
tests can be decided on immediately.
　In our study, the sensitivity of the NMP22BC test per-
formed on 1,070 patients who visited our hospital for hema-
turia or for follow-up observation of bladder cancer was 
77.5%, and the specificity was 88.8%. In other studies, Korean J Urol 2010;51:88-93
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Grossman et al reported a sensitivity of 55.7% and a specif-
icity of 85.7% for the NMP22BC test [12]. Tomera et al con-
ducted a prospective study of 1,300 patients with epithelial 
cell tumor symptoms or risk factors and performed 
NMP22BC tests, urine cytology, and cystoscopy [13]. For 
all disease stages, the sensitivity of the NMP22BC test was 
higher than the sensitivity of urine cytology; as the degree 
of cell differentiation increased, the sensitivity became 
higher [12].
　In our study, the sensitivity of the NMP22BC test was 
81.8% for non-muscle-invasive bladder cancer, which was 
higher than the sensitivity of 36.4% for urine cytology (p＜ 
0.01). For invasive cancer, the sensitivity of the NMP22BC 
test was 57.1%, which was lower than the 92.9% sensitivity 
of urine cytology; however, this difference was not statisti-
cally significant (p＞0.05). The sensitivity of the NMP22BC 
test for low-grade bladder cancer was 83.9% and for 
high-grade bladder cancer it was 62.5%. For urine cytology, 
sensitivity was 37.5% for low-grade bladder cancer and 
66.7% for high-grade bladder cancer (p＞0.05). Our results 
differ from other reports showing that, depending on dis-
ease stage and the differentiation grade of tumors, the sen-
sitivity of the NMP22 test tends to be increased [13].
　It thus appears that the NMP22BC test may be useful 
for the diagnosis of non-muscle-invasive bladder cancer as 
well as for low-grade cancer rather than for invasive and 
highly differentiated cancer, although additional studies 
are required. In our study, the sensitivity of urine cytology 
was 46.3% and the specificity was 97.9%, which is similar 
to the sensitivity (40-62%) and specificity (94-100%) of 
urine cytology reported elsewhere [4]. Among the 1,070 pa-
tients, 880 were seen for hematuria evaluation and 262 for 
follow-up of bladder cancer. The sensitivity and specificity 
of both groups showed trends similar to those of the overall 
group. Differences between the NMP22BC test and urine 
cytology in the group of follow-up patients were not statisti-
cally significant (Table 3). This finding of no significant dif-
ference in the cancer follow-up group is thought to be due 
to the small number of patients. Therefore, additional re-
search is needed.
　It is well known that for follow-up observation, the 
NMP22 test has the advantages of being noninvasive and 
being readily performed. However, it is not considered to 
be a method that can replace cystoscopy, and the most im-
portant reason for this may be its low specificity [9]. To ex-
plain the low specificity of the NMP22BC test, we per-
formed leukocyte analysis by microscopic urine testing by 
using the same specimen that had been used for the 
NMP22BC test. In cases with fewer than 5 white blood 
cells/HPF, the specificity of the NMP22BC test improved 
to 92.7% in the overall group. Also, the presence of pyuria 
in the group with hematuria and the group being followed 
up for bladder cancer was significantly associated with a 
lower specificity of the NMP22BC test (Table 6). According 
to urine cytology, the existence of pyuria contributed to the 
low specificity in all three groups (Table 7). Atsü et al also 
reported that cases with hematuria and pyuria are asso-
ciated with false-positives, which agrees with our findings 
[14]. The evaluation of hematuria was eliminated because 
our study included patients with hematuria. However, the 
low specificity of the NMP22BC test could not be explained 
completely by the above results. The exclusion of cases with 
inflammation within the bladder or infection, cases with 
a history of mechanical manipulation within the bladder, 
cases with foreign material within the bladder including 
urinary catheter insertion, and cases with tumors other 
than bladder cancer in the urogenital system could reduce 
the false-positive rate [15,16]. Sharma et al reported that 
when the above criteria were applied, the specificity and 
positive predictive rates of the NMP22BC test increased 
from 82% and 38.9% to 95.6% and 87.5%, respectively [17]. 
In our study, results with these exclusion criteria could not 
be obtained, and additional studies are required.
　The NMP22BC test detects changes at the molecular lev-
el and is not only more useful for the detection of tumors 
in the upper urinary tract [10] but is also easier to read. 
Thus, results obtained by specialists show a concurrence 
rate of between 91% and 95% [18].
CONCLUSIONS
The greater sensitivity of the NMP22BC test may be useful 
for the diagnosis of non-muscle-invasive and low-grade 
bladder cancer but not for the diagnosis of invasive and 
high-grade bladder cancers. Pyuria is one condition that 
decreases the specificity of the test. Thus, if the test is done 
for patients without pyuria, it may play a useful, compensa-
tory role relative to urine cytology.
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